Abiraterone acetate is an oral medication that has recently been granted approval for the treatment of metastatic castration resistant prostate cancer (mCRPC) prior and/or after chemotherapy with docetaxel.
In this article we assess the economics of abiraterone acetate in mCRPC. Relevant studies demonstrated that abiraterone acetate had a minimal budget impact on health plans. A relevant advantage was the cost savings due to the lack of chemotherapy-related side effects as well as the ease of administration. The results of cost/benefit comparative studies with other novel agents (i.e. cabazitaxel, enzalutamide, sipuleucel-T) are warranted as well as the close collaboration between urologists and medical oncologists.
Written by:
Dellis A, Papatsoris AG. Are you the author?
University Department of Urology, Sismanoglio General Hospital, Athens, Greece.
Reference: Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175-9.
doi: 10.1586/14737167.2014.891444
PubMed Abstract
PMID: 24564607
UroToday.com mCRPC Treatment Section
